Baerwald C, Kneitz C, Bach M, Licht M
Department für Innere Medizin, Neurologie und Dermatologie, Klinik für Gastroenterologie und Rheumatologie, Universitätsklinikum Leipzig AöR, Liebigstr. 18, 04103, Leipzig, Deutschland.
Z Rheumatol. 2012 Dec;71(10):841-9. doi: 10.1007/s00393-011-0928-x.
Rheumatoid arthritis (RA) represents an autoimmune disease affecting mostly joints, in particular small finger and toe joints. In addition RA can show extra-articular manifestations in many organs. Information on the frequency of extra-articular manifestations (EAMs) in RA varies greatly in different publications from 17.8% to 40.9% and EAMs tend to become higher with increasing duration and severity of the disease. The exact etiology and pathogenesis are still unclear but vasculitic alterations together with deposition of immune complexes can often be found histopathologically in affected organs. It must also be taken into consideration that EAMs can also be a result of the pharmaceutical therapy. The organ findings can vary greatly which is also reflected in the multitude of clinical symptoms. Possible target organs are the blood vessels, kidneys, central nervous system, cardiovascular system, the lungs, eyes, skin, nails as well as blood and the hemopoetic system. The prognosis for RA becomes progressively worse in the presence of EAMs. Regular and continuous control investigations are necessary in order to be able to diagnose EAMs early and to begin therapy. Therapy includes the administration of non-steroidal anti-inflammatory drugs (NSAIDs) and disease-modifying antirheumatic drugs (DMARDs) and especially in advanced stages cyclophosphamide or biologicals. Therapy is still very empirical due to the lack of appropriate studies.
类风湿关节炎(RA)是一种自身免疫性疾病,主要影响关节,尤其是手指和脚趾的小关节。此外,RA还可在许多器官表现出关节外症状。不同出版物中关于RA关节外表现(EAM)发生率的信息差异很大,从17.8%到40.9%不等,且EAM往往随着疾病持续时间和严重程度的增加而升高。确切的病因和发病机制仍不清楚,但在受影响器官的组织病理学检查中,常可发现血管炎改变以及免疫复合物沉积。还必须考虑到,EAM也可能是药物治疗的结果。器官表现差异很大,这也反映在众多的临床症状中。可能的靶器官包括血管、肾脏、中枢神经系统、心血管系统、肺、眼睛、皮肤、指甲以及血液和造血系统。存在EAM时,RA的预后会逐渐变差。为了能够早期诊断EAM并开始治疗,定期持续的对照检查是必要的。治疗包括使用非甾体抗炎药(NSAIDs)和改善病情抗风湿药(DMARDs),尤其是在疾病晚期使用环磷酰胺或生物制剂。由于缺乏适当的研究,治疗仍然非常经验性。